Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）

DRUG3 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen University

Conditions

Bladder CancerHepatocellular CarcinomaHepatocellular Carcinoma Non-resectableMuscle-invasive Bladder CancerNasopharyngeal Carcinoma (NPC)

Phase 1

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Not yet recruitingNCT06957561

Sun Yat-sen UniversityBladder Cancer, Muscle-invasive Bladder Cancer

Start: 2025-04-30End: 2029-05-01Target: 30Updated: 2025-05-04

Phase 2

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

RecruitingNCT06375486

Tianjin Medical University Cancer Institute and HospitalHepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable

Start: 2024-03-14End: 2026-06-15Target: 30Updated: 2024-04-19

Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Not yet recruitingNCT07064902

Sun Yat-sen UniversityNasopharyngeal Carcinoma (NPC)

Start: 2025-08-01End: 2028-06-30Target: 48Updated: 2025-07-18

Related Papers

Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study.

Journal of Clinical Oncology2025-05-28